Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a derivative of acetylsalicylic chemistry bearing a 4-trifluoromethyl substituent on the aromatic ring and an acetoxy function that facilitates rapid deacetylation. Chemically described as 2-acetoxy-4-(trifluoromethyl)benzoic acid, Triflusal exerts its antiplatelet effect through modulation of cyclooxygenase-dependent thromboxane A2 formation and by generation of an active hydroxy metabolite that contributes to nitric oxide signalling and cyclic AMP mediated platelet inhibition. The compound is orally absorbed, extensively protein bound, rapidly deacetylated by plasma and hepatic esterases to its primary active metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, and eliminated primarily via renal excretion of metabolites.
Parent: Triflusal
Typical quality specifications for active pharmaceutical ingredient batches set assay acceptance at not less than 98.0 percent by HPLC with related substances limits defined per ICH Q3A principles. Specified related compounds include the deacetylated hydroxy impurity (2-hydroxy-4-trifluoromethylbenzoic acid) with an individual limit commonly set at or below 0.30 percent, the des-acetylated positional isomer or degradant at or below 0.20 percent, and trifluoromethyl-phenol type impurities at or below 0.10 to 0.20 percent each. Total impurities are generally controlled to not exceed 1.0 percent. Unspecified single impurities are typically limited to 0.10 percent or less. Residual solvents are controlled to ICH Q3C class limits and heavy metals are held to pharmacopoeial thresholds; water content and loss on drying are controlled analytically to product-specific limits.
Triflusal is an antiplatelet agent classified as a platelet aggregation inhibitor; its primary pharmacology targets thromboxane A2 mediated platelet aggregation via cyclooxygenase modulation and downstream signalling pathways.
Yes, Triflusal is rapidly deacetylated in vivo to a principal active metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid, which contributes substantially to the overall antiplatelet effect; because the metabolite mediates much of the pharmacological activity, Triflusal is often regarded as a prodrug.
The parent ester has a relatively short plasma half-life on the order of one to a few hours due to rapid deacetylation, while the main active hydroxy metabolite exhibits a longer elimination half-life typically measured in several hours; reported values vary by study and assay conditions, so use product-specific pharmacokinetic data for precise values.
